| Execution period | 5 years |
|---|
BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,761.00
- Market cap
- ₹4,22,523 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 34.9×Sector 48.7×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharmaceutical Industries Credit Rating
Sun Pharma received credit ratings from CRISIL and ICRA for its proposed NCD programme and reaffirmed existing facility ratings.
Sun Pharmaceutical Industries Management Change
Sun Pharmaceutical Industries announced the resignation of Independent Director Gautam Doshi due to personal reasons.
Other management change announcements
All →Western Overseas Study Abroad Management Change
Western Overseas Study Abroad Ltd disclosed that Non-Executive Director Mr. Deepak Kumar resigned effective 30 October 2026. The board will note the resignation, citing other work commitments.
Divgi Torqtransfer Systems Management Change
Divgi TorqTransfer Systems appointed Mr. Sarang Deshpande as Company Secretary and Compliance Officer. Ms. Ishita Kokare resigned that role effective October 30, 2026.
Religare Enterprises Management Change
Religare Enterprises appointed Ms. Dipti Jayesh Khandelwal as Company Secretary and Compliance Officer w.e.f. October 31, 2026. She was designated as a Key Managerial Personnel.
Amanta Healthcare Management Change
Amanta Healthcare's COO Shri Anil Rathi resigned effective October 29, 2026. The departure is disclosed under Regulation 30 of the SEBI Listing Regulations.
Mastek Management Change
Mastek Ltd appointed Mr. Niraj Khemka as Vice President – Finance. He will also lead Investor Relations for the company.
Bharat Road Network Management Change
Ms. Ankita Rathi has resigned from her position as Company Secretary and Compliance Officer of Bharat Road Network Limited, effective from October 29, 2026.